PALISADE BIO, INC. (PALI) Debt Components
- 2021-12-31: Long-term Debt, Current MaturitiesUSD $87.00K; Long-term Debt, Excluding Current MaturitiesUSD $0.00; Long-term DebtUSD $87.00K; Long-Term Debt, Maturity, Year OneUSD (m).
- 2021-09-30: Long-term Debt, Current MaturitiesUSD $568.00K; Long-term Debt, Excluding Current MaturitiesUSD $0.00; Long-term DebtUSD $568.00K; Long-Term Debt, Maturity, Year OneUSD $346.00K.
- 2021-06-30: Long-term Debt, Current MaturitiesUSD $1.14M; Long-term Debt, Excluding Current MaturitiesUSD $0.00; Long-term DebtUSD $1.14M; Long-Term Debt, Maturity, Year OneUSD $602.00K.
- 2020-12-31: Long-term Debt, Current MaturitiesUSD $1.05M; Long-term Debt, Excluding Current MaturitiesUSD $94.00K; Long-term DebtUSD $1.14M; Long-Term Debt, Maturity, Year OneUSD (m).
PALISADE BIO, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Line of Credit Facility, Maximum Amount Outstanding During Period USD | Line of Credit Facility, Current Borrowing Capacity USD | Long-term Debt, Gross USD | Debt Instrument, Face Amount USD | Debt Instrument, Interest Rate, Effective Percentage pure | Debt Instrument, Basis Spread on Variable Rate pure | Debt Instrument, Periodic Payment USD | Debt Instrument, Unused Borrowing Capacity, Amount USD | Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate pure | Debt Instrument, Unamortized Discount USD | Debt Instrument, Interest Rate at Period End (Deprecated 2014-01-31) pure |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | $87.00K | $0.00 | $87.00K | (m) | (m) | (m) | (m) | (m) | (m) | $87.00K | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) |
| 2021-09-30 | $568.00K | $0.00 | $568.00K | $346.00K | $0.00 | $0.00 | $227.00K | (m) | (m) | $573.00K | (m) | (m) | (m) | (m) | (m) | (m) | $5.00K | (m) |
| 2021-06-30 | $1.14M | $0.00 | $1.14M | $602.00K | $0.00 | (m) | $553.00K | (m) | (m) | $1.16M | (m) | (m) | (m) | (m) | (m) | (m) | $14.00K | (m) |
| 2020-12-31 | $1.05M | $94.00K | $1.14M | (m) | (m) | (m) | (m) | (m) | (m) | $2.72M | (m) | (m) | (m) | (m) | (m) | (m) | $1.58M | (m) |
| 2017-03-31 | $2.53M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $3.71M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $4.83M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $5.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $300.00K | (m) | (m) | (m) | (m) |
| 2016-03-31 | $4.47M | $2.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 11.00% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $4.55M | $3.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $300.00K | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 11.00% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 9 month · $300.00K | (m) | (m) | (m) | (m) |
| 2015-09-30 | $4.46M | $4.63M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 11.00% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6 month · $300.00K | (m) | (m) | (m) | (m) |
| 2015-06-30 | $3.17M | $5.81M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 11.00% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $300.00K | (m) | (m) | (m) | (m) |
| 2015-03-31 | $1.93M | $6.95M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 11.00% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $730.01K | $8.06M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 11.00% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-10-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 10.00% | (m) | (m) |
| 2014-10-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $10.00M | (m) | (m) | (m) | (m) | 1 month · 10.00% | (m) | (m) | (m) | (m) | (m) |
| 2014-10-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $4.40M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $3.06M | $2.61M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 11.00% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $2.95M | $3.42M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 11.00% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $2.85M | $4.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $2.76M | $4.93M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 11.00% |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 11.00% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | $1.99M | $5.66M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 11.00% |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 11.00% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $1.24M | $6.36M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 11.00% |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $8.00M | (m) | (m) | (m) | (m) | $2.00M | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $8.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $510.67K | $7.04M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 11.00% |
| 2012-12-31 | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |